眼力健欲42亿美元收购竞争对手博士伦

　　Advanced Medical Optics Inc. on Thursday offered to buy eye-care products rival Bausch & Lomb Inc. for $4.23 billion in cash and stock， topping a $3.67 billion cash bid by a private equity firm.

　　AMO put in a $75-a-share offer of $45 in cash and $30 in AMO stock for each Bausch & Lomb share.

　　Bausch & Lomb said its board determined that the offer “is bona fide and is reasonably likely to result in a superior proposal.” It said it planned “to engage in further discussions” but cautioned that “there can be no assurances as to whether the AMO proposal will ultimately result in a transaction.”

　　Warburg Pincus， a buyout and venture capital firm in New York， won an agreement from Bausch & Lomb's board in mid-May to pay $65 a share for Bausch & Lomb. Bausch & Lomb's takeover agreement from Warburg Pincus allowed it to solicit other bids for 50 days.

　　The new offer came on the final day of a 50-day period that Bausch & Lomb set aside for other buyers to make a better bid. Under the deal with Warburg Pincus， Bausch & Lomb can solicit superior proposals until midnight Thursday but would have to pay a $40 million breakup fee if it accepts any other offer.

　　眼力健公司上周四宣布，欲以42．3亿美元收购竞争对手博士伦公司。这一价格超过此前一家私募股权基金公司提出的36．7亿美元收购报价。

　　眼力健提出每股75美元的价格收购博士伦，其中包括每股45美元现金加30美元

　　博士伦称眼力健的要约是“真诚的，并很有可能成为更优提议”。该公司计划与眼力健进行进一步磋商，但表示不保证最终能够达成交易。

　　今年5月中旬，博士伦与美国私募股权基金公司——华平创业投资有限公司达成以每股65美元的价格收购要约，但允许博士伦可以在50天之内寻找其他买家。

　　眼力健的收购要约是在50天期限的最后一天提出的。根据协议，如果博士伦在50天内，即到上周四午夜接受其他要约的话，其将要向华平创业投资有限公司支付4000万美元的违约金。